TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 18 years of age and in good general health as confirmed by a medical history.~* Females of childbearing potential must have a negative urine pregnancy test on Day 1 and must agree to use adequate birth control methods during the entire study.~* A clear diagnosis of plaque psoriasis must have been previously established and the disease must have been present at least 6 months.~* Subjects must have lesions suitable for evaluating response to test agents. The severity of the disease at Day 1 must be rated at least 2 (Mild) for each of the key psoriasis characteristics (scaling, erythema, and plaque elevation).~* Subjects must be able to understand the requirements of the study, abide by the restrictions, and return for the required examinations. All subject must sign the statement of informed consent approved for the study.~Exclusion Criteria:~* Subjects who are pregnant (determined from a urine pregnancy test on Day 1).~* Subjects who are nursing.~* Subjects with known hypersensitivity to any components of the test medication.~* Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. antibiotics, sedating antihistamines).~* Subjects using biologics or any other systemic treatment for psoriasis within 12 weeks of entering the study.~* Subjects using systemic corticosteroids within 28 days of entering the study; subjects using topical corticosteroids or other topical therapies (other than emollients) at any location on the body within 1 week of entering the study.~* Subjects with overt pre-existing telangiectasia or skin atrophy at intended treatment sites.~* Subjects who are using any medication or has any disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
- 2 (Type: PLACEBO_COMPARATOR): Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Device Testing to Promote Sleep in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 2-12 months.~2. Meets clinical criteria for behavioral insomnia of childhood, sleep association subtype, as defined by the International Classification of Sleep Disorders Manual.~Exclusion Criteria:~1. Diagnosed comorbid health problem that may disrupt sleep.~2. History of birth prior to 37 weeks gestational age.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Sleep Device intervention (Type: EXPERIMENTAL): Infants will utilize the sleep device during sleep for 20 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Impact of Patient-Centered Oncology Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Patients:~* Diagnosis of cancer~* Receives care at a pilot or comparison oncology practice located in southeastern Pennsylvania that accepts patients with Independence Blue Cross health insurance~Exclusion Criteria:~* Any person that does not meet any of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pilot Practices Patient Survey Cohort (Type: None): Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
- Comparison Practices Patient Survey Cohort (Type: None): Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
- Pilot Practices Utilization Cohort (Type: None): Patients with an evaluation \& management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
- Comparison Practices Utilization Cohort (Type: None): Patients with an evaluation \& management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
- Pilot Practices Quality Measures Cohort (Type: None): Patients with a new diagnosis of cancer in the past two years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Give their signed written informed consent to participate~2. At least 40 years of age and no older than 80 years of age~3. COPD patients who are symptomatic~4. Must be receiving one or more inhaled bronchodilators as maintenance therapy~5. Must have a documented history of COPD exacerbations~Exclusion Criteria:~1. Current diagnosis of asthma~2. COPD due to α1-Antitrypsin Deficiency~3. Known active tuberculosis, lung cancer, cystic fibrosis, and significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months.~4. Long-term-oxygen therapy (≥ 15 hours a day).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BFF MDI (PT009) 320/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- BFF MDI (PT009) 160/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- FF MDI (PT005) 9.6 μg (Type: EXPERIMENTAL): Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component~* Previous treatment with at least one anti-angiogenic agent~* Progressed within 6 months of study enrollment~* Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease~* Must have available tumor tissue for submission~* Subjects must also meet various laboratory parameters for inclusion~Exclusion Criteria:~* Subjects with any active autoimmune disease or a history of known autoimmune disease~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: nivolumab - 0.3 mg/kg (Type: EXPERIMENTAL): None
- Arm 2: nivolumab - 2.0 mg/kg (Type: EXPERIMENTAL): None
- Arm 3: nivolumab - 10.0 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with moderate to severe early rheumatoid arthritis (\< 2 years) who are methotrexate and biologic disease modifying antirheumatic drug naive.~Exclusion Criteria:~* Pregnant or lactating patients;~* Patients with renal or hepatic impairment or other severe or progressing disease;~* Patients with contraindication to magnetic resonance imaging with gadolinium contrast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (CP 690,550) 10 mg BID plus MTX (Type: EXPERIMENTAL): None
- Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX (Type: EXPERIMENTAL): None
- Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a life expectancy of at least 12 weeks~* Patients with advanced HCC (unresectable, and/or metastatic) which has been histologically or cytologically documented~* Patients must have at least one tumor lesion that meets both of the following criteria:~  * can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)~ * has not been previously treated with local therapy~* Patients who have received local therapy except chemoembolization, such as surgery, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. Local therapy must be completed at least 4 weeks prior to the baseline scan~* Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~Exclusion Criteria:~* Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated \> 3 years prior to entry is permitted~* History of cardiac disease~* Serious myocardial dysfunction~* Active, clinically serious infections~* Known history of Human Immunodeficiency Virus (HIV) infection~* Known Central Nervous System (CNS) tumors including metastatic brain disease~* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib + Doxorubicin (Type: EXPERIMENTAL): Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)
- Placebo + Doxorubicin (Type: ACTIVE_COMPARATOR): Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sydenham chorea moderate to severe (affecting activities of daily living) Raised ASOT titre~Exclusion Criteria:~* Mild Sydenham chorea (not affecting activities of daily living)~* Exclusion of systemic lupus erythematosus~* Exclusion of Wilson's disease~* Exclusion of toxin ingestion

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
- 2 (Type: PLACEBO_COMPARATOR): Group randomized to receive standard intervention for sydenham's chorea alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Medical Training for the Care of Chronic Conditions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Medical Students:~Inclusion: All medical students participating in diabetes Shared Medical Appointment sessions or other training experiences during the course of the study.~Exclusion Criteria:~medical students who have participated in SMAs for patients with diabetes at the Cleveland VAMC in the past.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Shared Medical Appointments (Type: EXPERIMENTAL): Medical students participated in shared medical appointments for patients with diabetes for one month.
- No shared medical appointments (Type: NO_INTERVENTION): Medical students in this arm did not participate in shared medical appointments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (18 years or older) of any race and either sex, requiring cataract extraction with planned implantation of a posterior chamber intraocular lens.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Under 18.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nepafenac (Type: EXPERIMENTAL): One drop in the study eye 3 times daily for 23 days
- Ketorolac Trometamol (Type: ACTIVE_COMPARATOR): One drop in the study eye 3 times daily for 23 days
- Nepafenac Vehicle (Type: PLACEBO_COMPARATOR): One drop in the study eye 3 times daily for 23 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Weight at least 40 kg~* A diagnosis of partial epilepsy according to the International League Against Epilepsy's Classification of Epileptic Seizures. Diagnosis should have been established by clinical history and an electroencephalogram (EEG) that is consistent with localization related epilepsy; normal interictal EEGs will be allowed provided that the subject meets the other diagnosis criterion (ie, clinical history)~* Have uncontrolled partial seizures despite having been treated with at least 1 AED within approximately the last 2 years~* During the 8-week baseline period, subjects must have at least 8 partial seizures including only simple partial seizures with motor component, complex partial seizures, or secondarily generalized seizures without a seizure-free interval of greater than 25 days any time during the 8 weeks baseline. Subjects must have at least 3 of these partial seizures during each of the two consecutive 4-week segments of the baseline period~* Currently on stable antiepileptic treatment regimen.~Exclusion Criteria:~* A history of nonepileptic or psychogenic seizures~* Presence of only nonmotor simple partial seizures or primary generalized epilepsies~* Presence or previous history of Lennox-Gastaut syndrome~* An active CNS infection, demyelinating disease, degenerative neurologic disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results~* Any clinically significant psychiatric illness, psychological, or behavioral problems that, in the opinion of the Investigator, would interfere with the subject's ability to participate in the study~* History of alcoholism, drug abuse, or drug addiction within the past 2 years~* History of status epilepticus within 3 months of Visit 1~* A yes answer to Question 1 or 2 of the C-SSRS (Baseline/Screening version) Ideation Section in the past 6 months or a yes answer to any of the Suicidal Behavior Questions in the past 2 years~* More than 1 lifetime suicide attempt~* Participation in any other trials involving an investigational product or device within 30 days of screening (or longer, as required by local regulations)~* A history of any previous exposure to YKP3089

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- YKP3089 Low Dose (Type: EXPERIMENTAL): YKP3089 Low Dose
- YKP3089 Medium Dose (Type: EXPERIMENTAL): YKP3089 Medium Dose
- YKP3089 High Dose (Type: EXPERIMENTAL): YKP3089 High Dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Provide informed consent~* Age ≥ 18 years and of either sex~* Willing to comply with protocol instructions, including allowing all study assessments~* Have a Venous Leg Ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 2.0 cm2 and ≤ 36.0 cm2~* Target ulcer duration ≥ 4 weeks but ≤ 104 weeks (24 months)~* Have a Diabetic Foot Ulcer (DFU) present on any part of the plantar or dorsum surface of the foot, with a surface area ≥ 0.5 cm2 and ≤ 10.0 cm2~* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone~* Target ulcer duration ≥ 4 weeks but ≤ 52 weeks (12 months)~* Acceptable state of health and nutrition~EXCLUSION CRITERIA~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study Ulcers which are deemed as highly exuding, per the Investigator's discretion.~* Current diagnosis of osteomyelitis at the target wound location that is not currently receiving treatment \[Documented history of resolved osteomyelitis is allowed\].~* Subjects with a VLU: Refusal of or inability to tolerate compression therapy.~* Clinical evidence of target ulcer infection~* Current systemic therapy with cytotoxic drugs.~* Current therapy with chronic (\> 10 days) oral corticosteroids.~* Previous treatment with NPWT device or hyperbaric oxygen within 7 days of screening.~* Malignancy in the target ulcer, or history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PICO System (Type: EXPERIMENTAL): Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
- tNPWT System (Type: ACTIVE_COMPARATOR): Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete